Alzheimer's Drug Discovery Foundation

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study

Retrieved on: 
Wednesday, February 28, 2024
Eli Lilly, African Americans, Merck, IXICO, Person, Research, Collaborative writing, Blood, AbbVie, Diagnosis, Volunteering, Digital technology, Roche, University, Biomarker, GAP, Journal, Disease, Alzheimer's Drug Discovery Foundation, White Americans, Brain, Amyloid plaques, PET, Biogen, Medical imaging

These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.

Key Points: 
  • These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.
  • GAP is proud that we succeeded in ensuring that the participants in this study reflected the diverse underrepresented populations afflicted with dementia.
  • With the recent approval of disease-modifying Alzheimer’s treatments, there is a growing need to simplify and accelerate an accurate diagnosis.
  • Dr. Richard Mohs observed that “This paper moves the field ahead in simplifying the diagnosis of Alzheimer’s disease.

Alzheimer's Drug Discovery Foundation (ADDF) Announces Launch of SpeechDx, the First Study to Generate a Voice Database Paired with Clinical Data for Early Detection of Alzheimer's Disease

Retrieved on: 
Monday, October 23, 2023
Fillit, Intelligence, Speech, Alzheimer's Drug Discovery Foundation, Neuroimaging, Biomarker, Gates Ventures, Human, Data, MD, Health, Doctor of Philosophy, Entrepreneurship, Dementia, Research, Tablet, BBRC, Disease, Ace, Machine learning, Emory University, Boston University, Brain, Algorithm, Language, Collection, Diagnosis, Dual-energy X-ray absorptiometry, Pharmaceutical industry, Medical imaging, Mobile phone, Alzheimer's disease

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.

Key Points: 
  • SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms.
  • Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
  • The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
  • Additionally, each participant's voice recording will be paired with clinical data and harmonized across all sites.

Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 17, 2023
Fillit, Momentum, Drug development, Amyloid, ET, Ageing, Alzheimer's Drug Discovery Foundation, Drug, Therapy, Doctor of Philosophy, Entrepreneurship, Inflammation, Research, Emerging, Boston Park Plaza, Plasma, Denali, Medicine, Biology, Brain, Cancer, Path, Fujirebio, Alzheimer's Research UK, Pharmaceutical industry, Medical imaging, Medical device, Alzheimer's disease, MD, Disease

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.

Key Points: 
  • This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's.
  • This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau.
  • The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
  • The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics.

Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science

Retrieved on: 
Thursday, October 5, 2023
Health, Hospitals, Practice Management, General Health, Research, Science, Learning, The Michael J. Fox Foundation, Data science, Alzheimer's Drug Discovery Foundation, COVID-19, Muscular dystrophy, Food, Biomarker, Muscular Dystrophy Association, Drug development, Human, Organization, Therapy, Motion, Neurology, 21st Century Cures Act, European Medicines Agency, Disease, Patient, FDA, Education, Drug discovery, Rare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Overalls, Registry, Pharmaceutical industry

Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.

Key Points: 
  • Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.
  • Nonprofit patient organizations have existed for more than 100 years and now number in excess of 3,000 in the United States.
  • The disease and mission focus of patient organizations has shifted and expanded over time as well.
  • As an example, more than 150 registries are now run by patient organizations, of which 62% focus on rare diseases, positioning patient organizations as custodians of data for their communities.

Revolutionizing Alzheimer's Prevention and Treatment: The Alzheimer's Drug Discovery Foundation and the FINGERS Brain Health Institute Announce Precision Prevention Partnership

Retrieved on: 
Wednesday, October 4, 2023
Fillit, Karolinska Institute, Medicine, Partnership, Drug development, Therapy, Senior, Prevalence, Diabetes, AARP, Alzheimer's Drug Discovery Foundation, Health, Cancer, Ageing, Brain, Risk, Biomarker, Inflammation, Doctor of Philosophy, Dementia, Organization, Incidence, Science, Physician, Patient, Drug discovery, Biology, Metformin, Gates Ventures, Entrepreneurship, FDA, Geriatrics, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, MD, Policy

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) announced today a new Precision Prevention Partnership, a unique collaboration set to transform the landscape of Alzheimer's disease prevention and treatment. Together, the ADDF and the FBHI will advance physicians' ability to tailor precision prevention approaches that combine lifestyle interventions and therapeutics to help delay or prevent the onset of the disease based on patients' individual risk and biomarker profiles.

Key Points: 
  • Alzheimer's is a complex disease, and a one size fits all approach will not effectively treat its varied causes and forms."
  • "With this new collaboration, our two organizations will redefine the prevention landscape by targeting several risk factors simultaneously to get optimal preventive effects against Alzheimer's disease."
  • This model will serve as a template for the next generation of combination clinical trials, helping to speed up the drug development pipeline.
  • Accelerating the development of new biomarkers for aging, helping improve Alzheimer's diagnostics and aiding in the development of novel drugs.

Dr. Rhoda Au Receives Prestigious Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development

Retrieved on: 
Wednesday, September 20, 2023
Fillit, Cognition, Inauguration, University, Marsha, Alzheimer's Drug Discovery Foundation, Ageing, Neuroscience, MBA, Research, Vanderbilt University, Doctor of Philosophy, Biomarker, Assistant, Boston University Chobanian & Avedisian School of Medicine, Tablet, Biochemistry, Molecular biology, Department of Pharmacology, University College London, Dementia, MD, Patient, Wake Forest University School of Business, Drug development, Biology, Diagnosis, Entrepreneurship, Digital, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, Anatomy, Pharmacology

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has presented Rhoda Au, PhD, MBA, Professor of Anatomy and Neurobiology at the Boston University Chobanian and Avedisian School of Medicine, with the 2023 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development for her pioneering work with digital biomarkers. The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.

Key Points: 
  • The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.
  • Au is the first researcher with work focused on diagnostic technologies to receive the Goodes Prize.
  • Au and her team is used to create digital profiles that can differentiate between people with stable cognition, cognitive decline, and dementia.
  • Au and our past winners today, it is easy to imagine that the next big breakthrough comes right here, through the ADDF and the Goodes Prize."

Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Retrieved on: 
Friday, August 18, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Neurology, Mental Health, Research, Science, Clinical Trials, Finance, Fillit, Therapy, Face, Drug discovery, Astrocyte, Stroke, Brain, TBI, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Inflammation, Patient, Alzheimer's Drug Discovery Foundation, Traumatic brain injury, Medicine, Entrepreneurship, Pharmaceutical industry, Alzheimer's disease

Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.

Key Points: 
  • Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.
  • “There are millions of patients living with brain injuries worldwide who face limited treatment options for these devastating conditions,” said William Korinek, Ph.D, CEO, Astrocyte Pharmaceuticals.
  • “Astrocyte has assembled an exceptional team of experts that are conducting research of the highest quality at every step,” commented Gorka Fius, CEO at Dreavent Capital who led the investment round.
  • “Finding innovative ways to target inflammation in the brain will play an important role in the future of combination therapy and precision medicine for Alzheimer's disease,” said Howard Fillit, M.D., Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation.

ALZpath Announces New Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay

Retrieved on: 
Tuesday, July 18, 2023
Fillit, LDT, Diagnosis, Drug discovery, Biogen, Alzheimer's Drug Discovery Foundation, Research, Brain, Biomarker, AAIC, RUO, MD, Patient, Physician, Blood, Entrepreneurship, FDA, Conference, Medical imaging, Pharmaceutical industry, Alzheimer's disease

CARLSBAD, Calif., July 18, 2023 /PRNewswire/ -- ALZpath, a leading developer of innovative diagnostic solutions for Alzheimer's disease, is proud to announce that they have received funding from the Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT). ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for Alzheimer's disease. The assay is performed on the Quanterix Simoa HD-X immunoassay analyzer.

Key Points: 
  • Funding will accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer's disease.
  • ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for Alzheimer's disease.
  • "The Alzheimer's Drug Discovery Foundation has had a transformative impact in advancing the understanding, diagnosis and treatment of Alzheimer's disease," said ALZpath Chief Scientific Officer and principal investigator, Dr. Andreas Jeromin.
  • Since 1998, the ADDF has awarded nearly $250 million in funding to over 720 Alzheimer's drug discovery and development programs, biomarker initiatives, and clinical trials in nineteen countries.

ALZpath Announces New Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay

Retrieved on: 
Tuesday, July 18, 2023
Fillit, LDT, Diagnosis, Drug discovery, Biogen, Alzheimer's Drug Discovery Foundation, Research, Brain, Biomarker, AAIC, RUO, MD, Patient, Physician, Blood, Entrepreneurship, FDA, Conference, Medical imaging, Pharmaceutical industry, Alzheimer's disease

CARLSBAD, Calif., July 18, 2023 /PRNewswire/ -- ALZpath, a leading developer of innovative diagnostic solutions for Alzheimer's disease, is proud to announce that they have received funding from the Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT). ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for Alzheimer's disease. The assay is performed on the Quanterix Simoa HD-X immunoassay analyzer.

Key Points: 
  • Funding will accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer's disease.
  • ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for Alzheimer's disease.
  • "The Alzheimer's Drug Discovery Foundation has had a transformative impact in advancing the understanding, diagnosis and treatment of Alzheimer's disease," said ALZpath Chief Scientific Officer and principal investigator, Dr. Andreas Jeromin.
  • Since 1998, the ADDF has awarded nearly $250 million in funding to over 720 Alzheimer's drug discovery and development programs, biomarker initiatives, and clinical trials in nineteen countries.

ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial

Retrieved on: 
Monday, July 17, 2023
Fillit, Optimism, JAMA, Alzheimer's Drug Discovery Foundation, Clinical trial, Ageing, Cancer, Research, Inflammation, Biomarker, Dementia, AAIC, Lilly, MD, Patient, Investment, Donanemab, Biology, Knowledge, Eli Lilly and Company, Entrepreneurship, FDA, III, Conference, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease

NEW YORK, July 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported by Eli Lilly and Company today for its anti-amyloid drug, donanemab, which was unveiled at the Alzheimer's Association International Conference (AAIC) in Amsterdam and published in JAMA. The data serve as another proof point that anti-amyloid therapies are just the first class of disease modifying therapies, further validating the ADDF's cornerstone belief that Alzheimer's will need to be treated with combination therapy, like other complex diseases of aging.

Key Points: 
  • Like in cancer, the goal is to address the many underlying pathologies of the disease through a precision medicine approach."
  • "Advancements in clinical trial design have been a driving force behind the recent Alzheimer's breakthroughs, and there's still more progress to come," notes Dr. Fillit.
  • The results of the TRAILBLAZER-ALZ 2 trial accelerate recent momentum, bringing us one step closer to making Alzheimer's a treatable, and eventually, a preventable disease."
  • Lilly has submitted donanemab to the FDA for traditional approval and a decision is expected to be announced by the end of the year.